ClinicalTrials.gg
Not yet recruitingNCT06984718Updated May 22, 2025

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

A Phase 2 interventional study of AK104+lenvatinib and lenvatinib in HCC and Hepatocellular Carcinoma, sponsored by Akeso. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-22.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cadonilimab in Carcinoma, Hepatocellular — 13 open to participants now, 16 under way, 2 of them phase 3. cadonilimab · Carcinoma, Hepatocellular.

Planned enrollment
3rd of 23
120 · median 36
Started
2025
with 2 others
Phase 2
16 of 23
8 open now
Primary completion
2026-11
later than 13 of 15 live
Registered
22nd of 23
by date
Lead sponsor
6 of 23
Akeso

Among the 23 studies testing cadonilimab in Carcinoma, Hepatocellular, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2025, is one of 16 in phase 2, reaches primary completion later than 13 of the 15 other live ones, and was the 22nd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

13 of the 23 studies testing cadonilimab in Carcinoma, Hepatocellular are open now, in 2 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About cadonilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cadonilimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have progressed on the first line treatment of atezolizumab and bevacizumab.

03

Conditions studied

  • HCC
  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed the Form (ICF) voluntarily.
  2. Age ≥18 years at time of signing ICF.
  3. Histologic or cytologic confirmation of HCC, or clinical diagnosis of HCC as per AASLD criteria.
  4. BCLC stage B or C, and not suitable for curative surgical or local therapy.
  5. Participants have progressed on the prior systemic treatment with atezolizumab plus bevacizumab combination treatment.
  6. At least one according to v1.1.
  7. Class A .
  8. performance status of 0 or 1.
  9. With a of ≥3 months.
  10. Adequate organ and hematologic function.

Exclusion criteria

Exclusion Criteria:

  1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
  2. Tumor thrombus invasion of superior mesenteric vein.
  3. Has a known history of, or any evidence of .
  4. Has received anti-cancer therapy for HCC within 3 weeks prior to the first dose of study treatment.
  5. Has received systemic anti-cancer therapy other than atezolizumab and bevacizumab.
  6. Has participated in another clinical study within 4 weeks prior to the first dose.
  7. History of liver transplantation.
  8. History of hepatic encephalopathy.
  9. Clinically symptomatic or recurrently drained pleural effusion, pericardial effusion, or ascites.
  10. History of bleeding event due to esophageal and/or gastric varices within 6 months prior to the first dose of study treatment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    AK104+lenvatinib

    AK104 IV plus lenvatinib orally

    Biological: AK104+lenvatinib

  • Active comparator
    lenvatinib

    lenvatinib orally

    Drug: lenvatinib

Interventions

  • BiologicalAK104+lenvatinib

    Drug pages: Cadonilimab · Lenvatinib

    Subjects will receive AK104+lenvatinib until disease progression

  • Subjects will receive lenvatinib until disease progression

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) per RECIST v1.1 by Blinded Independent Central Review (BICR)

    Proportion of subjects who have a complete or partial response relative to baseline as assessed by BICR according to RECIST v1.1.

    Time frame: Up to 24 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to 24 months

  2. Progression-free survival (PFS) assessed by investigator per RECIST v1.1

    PFS is defined as the time from randomization till the first documented disease progression (Per RECIST v1.1 assessed by the investigator) or death due to any cause, whichever occurs first.

    Time frame: Up to 24 months

  3. Duration of Response (DOR) assessed by investigator per RECIST v1.1

    DOR means time measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.

    Time frame: Up to 24 months

  4. Time to Response (TTR) assessed by investigator per RECIST v1.1

    TTR refers to Time to Response.

    Time frame: Up to 24 months

  5. Number of participants with adverse event (AE)

    The number of participants experiencing an Adverse Event (AE) and the severity of AEs will be assessed. AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment.

    Time frame: Up to 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Nov 2026, 17 months later.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 17 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
May 22, 2025
StartEst.
Jun 25, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Jun 30, 2027
Last update
May 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06984718
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
May 22, 2025
Start date
Jun 25, 2025 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 22, 2025

Study contacts

Ting Liu, M.D.
Contact
clinicaltrials@akesobio.com
(0760)89873999
Richard S. Finn, Ph.D.
principal investigator · Department of Medicine, University of California
Jian Zhou, Ph.D.
principal investigator · Fudan University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cadonilimab · Lenvatinib

Start the discussion